half yearly, gsk fim and strategic alliances, page-13

The main information I take from these last 2 anns is that most importantly everything progresses as anticipated.

We have had no surprises as yet with any of our partners, only continuous successful ticks of each testing stage,
that includes human testing.

A year ago we had engaged discussions on this forum wether we had any in vivo studies proving our technology.
Consensus was, that if we indeed would have succussfully conducted those tests, we would have the way free for commercialisation.

Now, a year later, we not only find out that human testing of a volunteer study has proven the expected correlation between in vitro and in vivo tests, we also know that these human tests were already replicated, showing us that already 2 clients found the same convergence between in vitro and in vivo results.
We all know how revolutionary the in vitro results were from the independent US Azopharma study in 2009, therefore a matched result from in vivo studies must be equally impressive.

Now we know we had 2 succussful in vivo studies in 2010 and market still ignores us and price is a third of what it was when we only had in vitro confirmation, it starts to be somewhat blindfolded.


Were we busy a year ago to argue that once in vivo and human studies would be successful behind us, we confidently would walk into license after license deal, I wonder what all the sceptics wait for now ?


Compared with other biotechs which provide successful in vivo studies, this is the time where they are snapped up by large pharmas for mergers, license deals, partnerships etc.
It happens at this current stage in the biotech testing pipeline, not at any later stage as human studies are the stage pharma management waits for to step in, particularly in the current global biotech climate which shows such appetite for business.

GSK will conduct its own human studies, as it probably already has, for every single product using our technology, but general proof of concept is now a given for OBJ's technologies.

Wait for more confirmation at your own financial peril, as rerating, like for so many other biotechs will come surprisingly and out of the blue as I read it so often when researching other breakthroughs I have tried to share with interested researchers on this forum.